I am a
Home I AM A Search Login

Papers of the Week

Papers: 16 Jul 2022 - 22 Jul 2022

Human Studies

2022 Jul 15


Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.


Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM, Thijs J, Romeijn GLE, Loman L, Schuttelaar M-L, van Wijk F, de Graaf M, de Bruin-Weller MS
Allergy. 2022 Jul 15.
PMID: 35837880.


At present no real-world studies are available on different dupilumab dosing regimens in controlled atopic dermatitis (AD). The aim of this study was to clinically evaluate a patient-centered dupilumab dosing regimen in patients with controlled AD and to relate this to serum drug levels and serum biomarkers.